

GLINE-2019-nCoV Ag Solution

Quick Perception in Real-time Screening

GLINE-2019-nCoV Ag assay is a colloidal gold immunoassay for the rapid qualitative determination of nucleocapsid protein of SARS-CoV-2 in human nasal or nasopharyngeal swab.

Your Test Choice in:


- Screening checkpoints of specific area: e.g. schools, airports, prisons, nursing homes, primary care, or other high risk congregate settings
- Daily self-check of healthcare personnel and emergency responders
- Home-based routine testing
- Regions with insufficient nucleic acid detection capabilities or unavailable
- Triaging individuals with respiratory symptoms in an emergency department or current outbreak situations

Features:


- Totally electronic equipment free
- Minimal operations required
- Results available within 15 minutes
- Support nasal/nasopharyngeal swab
- Operation environment: 20-30°C
- Storage environment: 2-30°C



Workflow of GLINE-2019-nCoV Ag:



Result Interpretation:



Clinical Significance of SARS-CoV-2 Ag Test


WHO Laboratory Testing Guidance for SARS-CoV-2:

Generally, the ease-of-use and rapid turnaround time of Ag-RDTs offers the potential to expand access to testing and decrease delays in diagnosis by shifting to decentralized testing of patients with early symptoms.

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays


Interim guidance
11 September 2020 World Health Organization

Identify the most infectious status of a COVID-19 positive person within the first seven days of symptom onset



(Giorgia Guglielmi. (2020) Fast coronavirus tests: what they can and can't do. Nature, 585: 496-498.)

Meet GLINE-2019-nCoV Family







SHENZHEN YHLO BIOTECH CO., LTD.

Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China

Tel: +86 755 26601910 Email: marketing@szyhlo.com Website: www.szyhlo.com